SCHEMBL11033865

SCHEMBL11033865

O=[N+]([O-])c1ccccc1-c1cscn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAOB P27338 1/20 0.47
MGAM O43451 1/20 0.45
GAA P10253 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
S100A4 P26447 2/20 0.44
PTPRC P08575 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27835711 0.94 ALDH1A1 (0.46) ALDH1A1TDP1MAOBMGAMGAA
SCHEMBL15318818 0.77 ALDH1A1 (0.57) ALDH1A1TDP1MAOBMGAMGAA
SCHEMBL14152959 0.74 HCAR1 (0.37) EIF4EHSD17B10
SCHEMBL444702 0.74 ALDH1A1 (0.53) ALDH1A1TDP1MAOBMGAMGAA
SCHEMBL4550545 0.73 LMNA (0.53) ALDH1A1TDP1MAOBMGAMGAA
SCHEMBL1287837 0.73 ALDH1A1 (0.74) ALDH1A1TDP1MGAMGAASI
SCHEMBL30535903 0.73 ALDH1A1 (0.74) ALDH1A1TDP1MGAMGAASI
SCHEMBL466425 0.73 IDO1 (0.46) ALDH1A1TDP1HDAC6IDO1METAP1
SCHEMBL15271176 0.72 KMT2A (0.55) ALDH1A1TDP1MAOBMGAMGAA
SCHEMBL16180458 0.72 ALDH1A1 (0.47) ALDH1A1TDP1MAOBMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042902-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-06 US disclosed
US-11897882-B2 Tricyclic crbn ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-02-13 US disclosed
US-20220306631-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-09-29 US disclosed
US-11292792-B2 Tricyclic CRBN ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-04-05 US disclosed
EP-3817748-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-05-12 EP disclosed
US-4514214-A Herbicidal sulfamates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-30 US disclosed
US-4475944-A PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-10-09 US disclosed
EP-0096593-A2 Herbicidal sulfamates E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292792-B2 Tricyclic CRBN ligands and uses thereof CRBN, CRKL, CUL4A ALDH1A1 4128/4885TDP1 2319/4885MAOB 2397/4885
US-11897882-B2 Tricyclic crbn ligands and uses thereof CRBN, CRKL, CUL4A ALDH1A1 4128/4885TDP1 2319/4885MAOB 2397/4885
US-20250042902-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF CRBN, CRKL, CUL4A ALDH1A1 4128/4885TDP1 2319/4885MAOB 2397/4885
US-20220306631-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF CRBN, CRKL, CUL4A ALDH1A1 4128/4885TDP1 2319/4885MAOB 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.